C&EN highlighted Nexo's $60 million Series A financing and its effort to apply covalent chemistry to cancer targets that have been difficult to drug with conventional approaches.
The article highlighted the company’s effort to move beyond conventional cysteine-centric approaches by broadening the range of amino acids that can be addressed with covalent chemistry. It also pointed to the platform’s potential to improve how potent and selective hit compounds are identified early in discovery.
C&EN covered Nexo’s launch with a short business brief focused on the company’s $60 million Series A financing and its plan to develop covalent drugs for previously intractable cancer targets. The piece framed Nexo as part of a broader push to apply chemistry innovation to difficult oncology programs.
Original coverage: C&EN